Does Rallies show Form 4 insider transactions for PRAX?

Yes. Rallies tracks PRAX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PRAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRAX. It does not provide personalized investment advice.

PRAX (Praxis Precision Medicines, Inc. Common Stock) Stock Analysis - Insider Trades

Praxis Precision Medicines, Inc. Common Stock (PRAX) is a publicly traded Healthcare sector company. As of May 20, 2026, PRAX trades at $335.76 with a market cap of $8.94B and a P/E ratio of -24.76. PRAX moved +4.66% today. Year to date, PRAX is +21.19%; over the trailing twelve months it is +745.37%. Its 52-week range spans $26.70 to $358.76. Analyst consensus is strong buy with an average price target of $643.38. Rallies surfaces PRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PRAX stock inside the company?

Recent PRAX insider activity includes Nemiroff Alex sold 1.71K, Nemiroff Alex sold 13.34K, Nemiroff Alex sold 977, Nemiroff Alex sold 9.10K, and Mastrocola Lauren sold 11.46K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PRAX Key Metrics

Key financial metrics for PRAX
Metric	Value
Price	$335.76
Market Cap	$8.94B
P/E Ratio	-24.76
EPS	$-13.48
Dividend Yield	0.00%
52-Week High	$358.76
52-Week Low	$26.70
Volume	230.75K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-303.27M
Gross Margin	0.00%

Recent PRAX Insider Trades

Nemiroff Alex sold 1.71K (~$327.14K) on Nov 20, 2025.
Nemiroff Alex sold 13.34K (~$2.57M) on Nov 20, 2025.
Nemiroff Alex sold 977 (~$188.79K) on Nov 20, 2025.
Nemiroff Alex sold 9.10K (~$1.77M) on Nov 20, 2025.
Mastrocola Lauren sold 11.46K (~$2.20M) on Nov 20, 2025.

Latest PRAX News

Truist Initiates Praxis Coverage with $715 Target, 112% Upside and FDA NDA Acceptances — May 13, 2026
Praxis drops as it posts Q1 results and updates NDA/clinical milestones — May 7, 2026
PRAX slips 3% as investors de-risk ahead of May 7 Q1 results and conferences — May 5, 2026
PRAX climbs as FDA accepts ulixacaltamide NDA, sets Jan. 29, 2027 decision date — May 4, 2026
Praxis Precision Medicines rises as dual FDA NDA reviews keep catalysts in focus — May 1, 2026

PRAX Analyst Consensus

16 analysts cover PRAX: 0 strong buy, 14 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $643.38.

Common questions about PRAX

Who is trading PRAX stock inside the company?: Recent PRAX insider activity includes Nemiroff Alex sold 1.71K, Nemiroff Alex sold 13.34K, Nemiroff Alex sold 977, Nemiroff Alex sold 9.10K, and Mastrocola Lauren sold 11.46K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PRAX?: Yes. Rallies tracks PRAX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PRAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRAX. It does not provide personalized investment advice.